Ulf Meyer-Hoffert, MD PhD, Department of Dermatology, Schittenhelmstr. 7, D-24105 Kiel, Germany, Tel.: +49 431 597 1513, Fax: +49 431 597 1611, E-mail:
Thromb Haemost. 2013 Sep;110(3):442-9. doi: 10.1160/TH12-11-0836. Epub 2013 Feb 28.
Kallikrein-related peptidases (KLKs) constitute a family of 15 highly conserved serine proteases, which show a tissue-specific expression profile. This made them valuable tumour expression markers. It became evident that KLKs are involved in many physiological processes like semen liquefaction and skin desquamation. More recently, we have learnt that they are involved in many pathophysiological conditions and diseases making them promising target of therapeutic intervention. Therefore, regulation of KLKs raised the interest of numerous reports. Herein, we summarise the current knowledge on KLKs regulation with an emphasis on skin-relevant KLKs regulation processes. Regulation of KLKs takes place on the level of transcription, on protease activation and on protease inactivation. A variety of protease inhibitors has been described to interact with KLKs including the irreversible serine protease inhibitors (SERPINs) and the reversible serine protease inhibitors of Kazal-type (SPINKs). In an attempt to integrate current knowledge, we propose that KLK regulation has credentials as targets for therapeutic intervention.
激肽释放酶相关肽酶(KLKs)构成了一个由 15 种高度保守的丝氨酸蛋白酶组成的家族,它们表现出组织特异性的表达谱。这使它们成为有价值的肿瘤表达标志物。很明显,KLKs 参与了许多生理过程,如精液液化和皮肤脱屑。最近,我们了解到它们还参与了许多病理生理状况和疾病,使它们成为有前途的治疗干预靶点。因此,KLKs 的调节引起了众多报告的关注。本文总结了目前关于 KLKs 调节的知识,重点介绍了与皮肤相关的 KLKs 调节过程。KLKs 的调节发生在转录水平、蛋白酶激活和蛋白酶失活水平。已经描述了多种蛋白酶抑制剂与 KLKs 相互作用,包括不可逆丝氨酸蛋白酶抑制剂(SERPINs)和 Kazal 型可逆丝氨酸蛋白酶抑制剂(SPINKs)。为了整合当前的知识,我们提出 KLK 调节可以作为治疗干预的靶点。